These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Mechanisms for formation of myeloma bone disease]. Yata K; Abe M; Matsumoto T Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024 [TBL] [Abstract][Full Text] [Related]
3. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Pearse RN Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6274s-6278s. PubMed ID: 17062713 [TBL] [Abstract][Full Text] [Related]
4. [Bone disease in multiple myeloma and its mechanism]. Abe M Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506 [TBL] [Abstract][Full Text] [Related]
5. The pathogenesis of the bone disease of multiple myeloma. Edwards CM; Zhuang J; Mundy GR Bone; 2008 Jun; 42(6):1007-13. PubMed ID: 18406675 [TBL] [Abstract][Full Text] [Related]
6. Multiple Myeloma and Bone: The Fatal Interaction. Marino S; Roodman GD Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29229668 [TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of multiple myeloma bone disease. Lentzsch S; Ehrlich LA; Roodman GD Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587 [TBL] [Abstract][Full Text] [Related]
8. [Link between osteoclastogenesis, angiogenesis and myeloma expansion]. Abe M Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029 [TBL] [Abstract][Full Text] [Related]
10. Nonsecretory multiple myeloma with osteoporosis: immunocytologic and bone resorptive studies. Van Slyck EJ; Kleerekoper M; Abraham JP; Deegan MJ Am J Med Sci; 1986 May; 291(5):347-51. PubMed ID: 3518452 [TBL] [Abstract][Full Text] [Related]
11. Microdamage detection and repair in bone: fracture mechanics, histology, cell biology. Hazenberg JG; Hentunen TA; Heino TJ; Kurata K; Lee TC; Taylor D Technol Health Care; 2009; 17(1):67-75. PubMed ID: 19478407 [TBL] [Abstract][Full Text] [Related]
12. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429 [TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925 [TBL] [Abstract][Full Text] [Related]
14. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276 [TBL] [Abstract][Full Text] [Related]
16. Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Yajima A; Inaba M; Tominaga Y; Ito A Am J Kidney Dis; 2007 Mar; 49(3):440-51. PubMed ID: 17336706 [TBL] [Abstract][Full Text] [Related]
17. The role of bone in osteoarthritis pathogenesis. Goldring SR Rheum Dis Clin North Am; 2008 Aug; 34(3):561-71. PubMed ID: 18687272 [TBL] [Abstract][Full Text] [Related]
18. [Assessment of bone quality. Bone remodeling and bone quality]. Sano G; Matsuo K Clin Calcium; 2008 Mar; 18(3):315-20. PubMed ID: 18310818 [TBL] [Abstract][Full Text] [Related]